This Morning's Technical Outlook on Drug Makers Stocks -- Synergy Pharma, Depomed, United Therapeutics, and Novo Nordisk

Wednesday, December 20, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Dec. 20, 2017 /PRNewswire/ --

In keeping with the commitment to dynamically provide members with timely

information, has issued free tailored Stock Review on SGYP, DEPO, UTHR, and NVO which is a click away at Today's research on is focused on select Drug Manufacturers stocks,
particularly, Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Depomed Inc. (NASDAQ: DEPO), United Therapeutics Corp. (NASDAQ: UTHR), and Novo Nordisk A/S (NYSE: NVO). The Pharmaceutical Manufacturing sector consists of establishments primarily engaged in one or more of the following: manufacturing biological and medical products; processing botanical drugs and herbs; isolating active medical principles from botanical drugs and herbs; and manufacturing pharmaceutical products intended for internal and external consumption. With Wall St. Equities' free research reports get an edge over stock markets, sign up now at:

Synergy Pharmaceuticals

New York headquartered Synergy Pharmaceuticals Inc.'s shares gained 2.50%, closing Tuesday's trading session at $2.05. The stock recorded a trading volume of 6.64 million shares. The Company's shares have advanced 5.13% in the last month. The stock is trading 15.87% below its 50-day moving average. Additionally, shares of Synergy Pharma, which focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders, have a Relative Strength Index (RSI) of 48.11. Our free and thorough report on SGYP awaits you at:


On Tuesday, shares in Newark, California headquartered Depomed Inc. recorded a trading volume of 1.18 million shares. The stock rose 0.46%, ending the day at $8.65. The Company's shares have surged 39.97% in the past month and 45.62% in the previous three months. The stock is trading above its 50-day moving average by 39.48%. Furthermore, shares of Depomed, which engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the US, have an RSI of 75.59.  

On December 04th, 2017, Depomed announced that it has signed a definitive Commercialization Agreement with Collegium Pharmaceutical, Inc. ("Collegium"). Under the terms of agreement, Collegium will commercialize both NUCYNTA® Extended Release and NUCYNTA® Immediate Release ("NUCYNTA"). In exchange for the commercialization of NUCYNTA, Depomed will receive a royalty rate on all NUCYNTA revenues based on certain net sales thresholds.  

On December 05th, 2017, research firm Mizuho upgraded the Company's stock rating from 'Neutral' to 'Buy', with a target price of $9 per share. DEPO's complimentary research coverage is a few simple steps away at:

United Therapeutics

Silver Spring, Maryland headquartered United Therapeutics Corp.'s stock finished the day 0.51% lower at $135.52. A total volume of 521,261 shares was traded, which was above their three months average volume of 399,540 shares. The Company's shares have advanced 10.16% in the last one month and 15.27% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 8.39% and 6.40%, respectively. Additionally, shares of United Therapeutics, which develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide, have an RSI of 62.92. Register for your free research report on UTHR at:

Novo Nordisk

Shares in Bagsvaerd, Denmark headquartered Novo Nordisk A/S ended yesterday's session 0.25% lower at $52.79. The stock recorded a trading volume of 1.04 million shares. The Company's shares have advanced 3.69% in the last one month, 7.49% over the previous three months, and 47.21% since the start of this year. The stock is trading 4.25% and 19.86% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Novo Nordisk, which engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide, have an RSI of 57.74.

On December 06th, 2017, research firm Bank of America/ Merrill upgraded the Company's stock rating from 'Neutral' to 'Buy'. Wall St. Equities' downloadable research report on NVO available at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Cision View original content:

SOURCE Wall St. Equities


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store